Loading…
Loading…
An AI mental-health companion offering CBT/DBT/ACT guided reflection, mood tracking and daily wellbeing support.
Visit Official WebsiteData may be delayed — always check the official website for the latest info.
Visit Official WebsiteBudd is an always-on AI mental-health companion that delivers conversational guidance rooted in evidence-based CBT, DBT and ACT. It first listens to surface your emotional patterns and triggers, then builds a personalized care plan — cognitive restructuring, 5-4-5 breathing, gratitude journaling and more. The platform offers mood/stress tracking, goal breakdowns, habit building and weekly challenges, with crisis-resource guidance when appropriate. The free tier includes 50 messages/month and 20 starter exercises; Premium (£29.99/mo) unlocks unlimited chat, voice interaction, a 150+ exercise library and downloadable progress reports. Conversations are encrypted and UK-GDPR compliant, positioned explicitly as a complement — not a replacement — for professional care.
Budd is built by The International Psychology Clinic Ltd (team of clinical psychologist Dr. Martina Paglia) and launched its mobile app in March 2026. It is a 24/7 AI mental-health companion that draws on a million-scale clinical knowledge base to help users self-reflect, regulate stress and build psychological resilience.
Built on evidence-based CBT, DBT and ACT frameworks, Budd combines mood/stress tracking, guided assessments (e.g. PHQ-9, GAD-7) and habit/goal management; Premium adds WhatsApp voice notes and a 150+ exercise library. Per the team, the model was trained on 100K+ peer-reviewed papers, 10K+ hours of lectures and 5K+ psychotherapy case studies.
Targets the general public dealing with everyday stress, anxiety and emotional challenges who want self-growth — offering low-cost, accessible AI therapeutic conversation to bridge the gaps between sessions with a human professional (not a medical substitute).
Turns evidence-based CBT/DBT/ACT into approachable AI chat; mood tracking and personalized plans are standout strengths, but efficacy lacks independent clinical validation and the free quota is small.
All information on this site is for reference only. Data may be delayed — always verify on the official website. Listings are in no particular order.